All In Biotech

NDA 209388 · Qol Medcl

Gimoti

Metoclopramide Hydrochloride · Nasal

Last checked: Nov 20, 2026Latest source record: Feb 9, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Jun 19, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

192

38 Phase 3, 6 recruiting

FAERS reports

9,040

7,706 serious, 1,097 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: TARDIVE DYSKINESIA Metoclopramide, including GIMOTI, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder. In patients treated with metoclopramide, including GIMOTI, the risk of developing TD increases with duration of treatment and total cumulative dosage [see Warnings and Precautions ( 5.1 )] . GIMOTI is contraindicated in patients with a history of TD. Use GIMOTI for the shortest duration of treatment and periodically reassess the need for continued treatment. Immediately discontinue GIMOTI in patients who develop signs or symptoms of TD [see Warnings and Precautions ( 5.1 )] . Avoid a total duration of treatment with metoclopramide products, including GIMOTI, for longer than 12 weeks. If longer-term use is unavoidable, routinely monitor for signs and symptoms of TD [see Warnings and Precautions ( 5.1 )] . WARNING: TARDIVE DYSKINESIA See...

What it is approved for

From the label in effect Feb 20, 2026.

GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. GIMOTI is a dopamine-2 (D 2 ) antagonist indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. ( 1 ) Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates. ( 1 , 8.4 ) moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions. ( 1 , 5.9 , 7.1 ) Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions [see Warnings and Precautions ( 5.9 )]. Limitations of Use : GIMOTI is not recommended for use in: pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates [see Use in Specific Populations ( 8.4 )]. moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of...

Mechanism: Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize tissues to the action of acetylcholine. The effect of metoclopramide on motility is not dependent on intact vagal innervation, but it can be abolished by anticholinergic drugs. Metoclopramide increases the tone and amplitude of gastric (especially antral) contractions,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jun 19, 2020 Original approval · Type 3 - New Dosage Form and Type 4 - New Combination LabelLetterReview
1 products under this application
  • GIMOTI · METOCLOPRAMIDE HYDROCHLORIDE EQ 15MG BASE/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoclopramide" as an intervention, any sponsor and status, largest first.

All 192 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • tardive dyskinesia2,414
  • extrapyramidal disorder1,094
  • nausea829
  • incorrect drug administration duration691
  • off label use605
  • diarrhoea507
  • vomiting486
  • drug ineffective419
  • nervous system disorder404
  • pyrexia379
  • headache371
  • tremor365

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200452
200566
200646
200756
200857
2009101
2010243
20112,040
2012331
2013353
2014358
201577
2016116
2017169
2018207
2019297
2020300
2021586
2022905
2023840
2024782
2025647
2026407

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Gimoti (Metoclopramide HCl)

2024 spending

$4.6M

Beneficiaries

707

2,151 claims

Per beneficiary

$6,437

$210.71 per unit

View as table
YearSpending
2020$0
2021$374,428
2022$1,393,712
2023$2,946,429
2024$4,551,069

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,550 on PubMed

Sponsor: Qol Medcl

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.